Monitor for actual sales under this equity line, which would provide cash but increase dilution. The stock's OTC listing and history of dilutive financings suggest continued pressure on share price. The ongoing litigation with Pooph Inc. and substantial doubt about going concern status add significant risk.
Executive Summary
BioLargo is registering 30 million shares for resale by Clearthink Capital Partners under a $10 million equity line agreement. The company will not receive proceeds from the resale but may receive up to $10 million by selling shares to Clearthink at a price equal to the average of the two lowest closing prices over the prior eight trading days. This offering will dilute existing shareholders and adds to the company's history of raising capital through dilutive financings.
Key Financial Metrics
Key Facts
- 30 million shares registered for resale by Clearthink Capital Partners
- Company may sell up to $10 million of shares to Clearthink under equity line agreement
- Purchase price based on average of two lowest closing prices over prior eight trading days
- Company will not receive proceeds from resale by Clearthink
- Significant dilution to existing shareholders (8.6% of outstanding shares)
- Company has history of losses and negative cash flow, raising substantial doubt about going concern
Financial Impact
Up to $10 million in potential proceeds to the company from selling shares to Clearthink, with 8.6% dilution if all 30 million shares are issued
Risk Factors
- Dilution from equity line and other financings
- Substantial doubt about going concern status
- Ongoing litigation with former major customer Pooph Inc.
- History of net losses and negative cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001437749-26-012699 |
| Document: 0001437749-26-012699-index-headers.html | 0001437749-26-012699 |
| Document: 0001437749-26-012699-index.html | 0001437749-26-012699 |
| Document: 0001437749-26-012699.txt | 0001437749-26-012699 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.0700 | awaiting T+60 | — | $0.0680 (+2.86%) |
Sep 11, 2026 6w ago | 8-K | $0.1000 | awaiting T+60 | — | $0.0680 (−32.00%) |
May 4, 2026 25w ago | 8-K | $0.1600 $0.1117 | ▼ −30.19% | ▼ −32.04% | $0.0680 (−57.50%) |
Apr 17, 2026 27w ago | 424B4 | $0.1500 $0.1120 | ▲ +25.33% | ▲ +32.11% | $0.0680 (+54.67%) |
Apr 17, 2026 27w ago | 424B4 | $0.1500 $0.1120 | ▲ +25.33% | ▲ +32.11% | $0.0680 (+54.67%) |
Mar 5, 2026 33w ago | 8-K | $0.1700 $0.1200 | ▲ +29.41% | ▲ +40.71% | $0.0680 (+60.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers